ACT_547520/2023
DexCom Inc. brought an infringement action against multiple Abbott entities before the Munich Local Division concerning EP 3 350 592 (a CGM system patent). Abbott counterclaimed for revocation and succeeded: the court found the patent invalid for lack of novelty/inventive step both as granted and in DexCom's two auxiliary request forms, and revoked it entirely. DexCom's failure to advance specific arguments distinguishing the dependent claims was noted as a further reason those claims fell. All infringement claims were dismissed and DexCom was ordered to bear all costs.
Patent EP 3 350 592 invalid as granted and in all auxiliary request forms
RespondentLegal basis: Art. 138(1) EPC; Art. 65(2) UPCANote: Munich LD upheld Abbott's counterclaim for revocation, finding the CGM patent invalid for lack of novelty/inventive step in all claim versions.
Dependent claims are invalid for same reasons as claim 1 where claimant provides no specific arguments distinguishing dependent claims
RespondentLegal basis: Art. 138(1) EPCNote: Claimant merely asserted dependent claims contain claim 1 features and are novel/inventive for the same reasons; no specific arguments advanced; court held dependent claims also invalid.
EP 3 350 592 as granted is valid
ClaimantLegal basis: Art. 54/56 EPCReason: Patent found invalid for lack of novelty/inventive step as granted.
Auxiliary requests 1 and 2 are valid
ClaimantLegal basis: Art. 54/56 EPCReason: Both auxiliary requests also found invalid; dismissed.
Browse other cases on this principle.